Document:

Amended and Restated Common Stock Purchase Warrant

 Exhibit 10.73 
  
 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO ACCENTIA BIOPHARMACEUTICALS, INC. THAT SUCH REGISTRATION IS NOT REQUIRED. 
  
 Right to Purchase up to the Maximum Number of Warrant Shares (as defined
below) of 
 Common Stock of Accentia Biopharmaceuticals, Inc. 
 (subject to adjustment as provided herein) 
  
 AMENDED AND RESTATED 
 COMMON STOCK PURCHASE WARRANT 
  

			
	 No.
                    
	 	Issue Date: August 16, 2005

  
 ACCENTIA
BIOPHARMACEUTICALS, INC., a corporation organized under the laws of the State of Florida (the “Company”), hereby certifies that, for value received, LAURUS MASTER FUND, LTD., or assigns (the “Holder”), is entitled, subject to the
terms set forth below, to purchase from the Company (as defined herein) from and after the Issue Date of this Warrant and at any time or from time to time before 5:00 p.m., New York time, through the close of business August 16, 2010 (the
“Expiration Date”), up to such number of fully paid and nonassessable shares of Common Stock (as hereinafter defined), $0.001 par value per share (the “Maximum Number of Warrant Shares”) as shall be determined by dividing
$8,000,000 by the initial issuance price of shares of Common Stock sold through the initial public offering of the Common Stock (the “Initial Public Offering”), at the applicable Exercise Price per share (as defined below); provided that
if by the 270th day following the date hereof an initial public offering of Common Stock has not taken place, the
defined term Maximum Number of Warrant Shares shall mean 979,312 shares of Common Stock until such time as an Initial Public Offering shall occur. The number and character of such shares of Common Stock and the applicable Exercise Price per share
are subject to adjustment as provided herein. 
  
 As used herein
the following terms, unless the context otherwise requires, have the following respective meanings: 
  
 (a) The term “Company” shall include Accentia Biopharmaceuticals, Inc. and any person or entity that shall succeed, or assume
the obligations of, Accentia Biopharmaceuticals, Inc. hereunder. 
  
 (b) The term “Common Stock” includes (i) the Company’s Common Stock, par value $0.001 per share; and (ii) any other securities into which or for which any of the securities described in the preceding
clause (i) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise. 

 (c) The term “Other Securities” refers to any stock (other than Common Stock)
and other securities of the Company or any other person (corporate or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise of the Warrant, in lieu of or in addition to Common
Stock, or which at any time shall be issuable or shall have been issued in exchange for or in replacement of Common Stock or Other Securities pursuant to Section 4 or otherwise. 
  
 (d) The “Exercise Price” applicable under this Warrant shall be equal to $8.169; provided
that, on the date of consummation of the initial public offering of Common Stock, the “Exercise Price” shall be adjusted to an amount equal to the issuance price of the Common Stock issued in connection with such initial public
offering (the “IPO Price”). For the avoidance of doubt, the “Exercise Price”, and the number of shares of Common Stock issuable upon exercise of this Warrant, as described herein have been determined taking into account the 1 for
2.1052 reverse stock split effected on May 16, 2005. 
  
 (e) The “Effective Date” shall mean the earlier to occur of (x) 180 days following the initial date of effectiveness of the Registration Statement referred to, and as defined, in that certain Registration Rights Agreement (as
defined in the Securities Purchase Agreement, dated as of April 29, 2005 between the Holder and the Company), by and between the Holder and the Company, (y) the date on which the entire amount outstanding (including, without limitation, principal,
interest and fees) under the Note (as defined in the Securities Purchase Agreement) has either been fully converted into Common Stock and/or been repaid in full in cash and (z) the occurrence and continuance of an Event of Default (as defined in the
Note (as defined in the Securities Purchase Agreement)). 
  
 1.
Exercise of Warrant. 
  
 1.1 Number of Shares Issuable
upon Exercise. From and after the date hereof through and including the Expiration Date, the Holder shall be entitled to receive, upon exercise of this Warrant in whole or in part, by delivery of an original or fax copy of an exercise notice in
the form attached hereto as Exhibit A (the “Exercise Notice”), shares of Common Stock of the Company, subject to adjustment pursuant to Section 4. 
  
 1.2 Fair Market Value. For purposes hereof, the “Fair Market Value” of a share of Common Stock as of a particular date (the
“Determination Date”) shall mean: 
  
 (a) If the Company’s Common Stock is traded on the American Stock Exchange or another national exchange or is quoted on the National or SmallCap Market of The Nasdaq Stock Market, Inc. (“Nasdaq”), then the closing or last
sale price, respectively, reported for the last business day immediately preceding the Determination Date. 
  

 2 

 (b) If the Company’s Common Stock is not traded on the American Stock Exchange or
another national exchange or on the Nasdaq but is traded on the NASD Over The Counter Bulletin Board, then the mean of the average of the closing bid and asked prices reported for the last business day immediately preceding the Determination Date.

  
 (c) Except as provided in clause (d) below,
if the Company’s Common Stock is not publicly traded, then as the Holder and the Company agree or in the absence of agreement by arbitration in accordance with the rules then in effect of the American Arbitration Association, before a single
arbitrator to be chosen from a panel of persons qualified by education and training to pass on the matter to be decided. 
  
 (d) If the Determination Date is the date of a liquidation, dissolution or winding up, or any event deemed to be a liquidation,
dissolution or winding up pursuant to the Company’s charter, then all amounts to be payable per share to holders of the Common Stock pursuant to the charter in the event of such liquidation, dissolution or winding up, plus all other amounts to
be payable per share in respect of the Common Stock in liquidation under the charter, assuming for the purposes of this clause (d) that all of the shares of Common Stock then issuable upon exercise of the Warrant are outstanding at the Determination
Date. 
  
 1.3 Company Acknowledgment. The Company will, at
the time of the exercise of this Warrant, upon the request of the holder hereof acknowledge in writing its continuing obligation to afford to such holder any rights to which such holder shall continue to be entitled after such exercise in accordance
with the provisions of this Warrant. If the holder shall fail to make any such request, such failure shall not affect the continuing obligation of the Company to afford to such holder any such rights. 
  
 1.4 Trustee for Warrant Holders. In the event that a bank or trust
company shall have been appointed as trustee for the holders of this Warrant pursuant to Subsection 3.2, such bank or trust company shall have all the powers and duties of a warrant agent (as hereinafter described) and shall accept, in its own name
for the account of the Company or such successor person as may be entitled thereto, all amounts otherwise payable to the Company or such successor, as the case may be, on exercise of this Warrant pursuant to this Section 1. 
  
 1.5 Further Exercise Limitation. Notwithstanding anything contained
herein to the contrary, the Holder shall not be entitled to exercise this Warrant, in whole or in part, prior to the earlier to occur of (i) two hundred seventy (270) days after the date hereof and (i) one hundred eighty (180) days after the date of
the initial public offering of Common Stock. The limitation described in this Section 1.5 shall automatically become null and void without any notice to any Company upon the occurrence and during the continuance of an Event of Default. 

 

 3 

 2. Procedure for Exercise. 
  
 2.1 Delivery of Stock Certificates, Etc., on Exercise. The Company agrees that the shares of Common Stock purchased
upon exercise of this Warrant shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been surrendered and payment made for such shares in accordance
herewith. As soon as practicable after the exercise of this Warrant in full or in part, and in any event within three (3) business days thereafter, the Company at its expense (including the payment by it of any applicable issue taxes) will cause to
be issued in the name of and delivered to the Holder, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct in compliance with applicable securities laws, a certificate or certificates for the number of duly and
validly issued, fully paid and nonassessable shares of Common Stock (or Other Securities) to which such Holder shall be entitled on such exercise, plus, in lieu of any fractional share to which such holder would otherwise be entitled, cash equal to
such fraction multiplied by the then Fair Market Value of one full share, together with any other stock or other securities and property (including cash, where applicable) to which such Holder is entitled upon such exercise pursuant to Section 1 or
otherwise. 
  
 2.2 Exercise. 
  
 (a) Payment may be made either (i) in cash or by certified
or official bank check payable to the order of the Company equal to the applicable aggregate Exercise Price, (ii) by delivery of this Warrant, or shares of Common Stock and/or Common Stock receivable upon exercise of this Warrant in accordance with
the formula set forth in subsection (b) below, or (iii) by a combination of any of the foregoing methods, for the number of Common Shares specified in such Exercise Notice (as such exercise number shall be adjusted to reflect any adjustment in the
total number of shares of Common Stock issuable to the Holder per the terms of this Warrant) and the Holder shall thereupon be entitled to receive the number of duly authorized, validly issued, fully-paid and non-assessable shares of Common Stock
(or Other Securities) determined as provided herein. 
  
 (b) Notwithstanding any provisions herein to the contrary, if the Fair Market Value of one share of Common Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant for
cash, the Holder may elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together with the properly endorsed
Exercise Notice in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the following formula: 
  

			
	 X=
	 	   Y(A-B)  

	 	 	      A

		
	 Where X =
	 	 the number of shares of Common Stock to be issued to the Holder

		
	 Y =
	 	the number of shares of Common Stock purchasable under this Warrant or, if only a portion of this Warrant is being exercised, the portion of this Warrant being exercised (at the date of such
calculation)

  

 4 

			
	 A =
	  	     the Fair Market Value of one share of the Company’s Common Stock (at the date of such
calculation)

		
	 B =
	  	     the Exercise Price per share (as adjusted to the date of such calculation)

  
 3. Effect of
Reorganization, Etc.; Adjustment of Exercise Price. 
  
 3.1
Reorganization, Consolidation, Merger, Etc. In case at any time or from time to time, the Company shall (a) effect a reorganization, (b) consolidate with or merge into any other person, or (c) transfer all or substantially all of its
properties or assets to any other person under any plan or arrangement contemplating the dissolution of the Company, then, in each such case, as a condition to the consummation of such a transaction, proper and adequate provision shall be made by
the Company whereby the Holder, on the exercise hereof as provided in Section 1 at any time after the consummation of such reorganization, consolidation or merger or the effective date of such dissolution, as the case may be, shall receive, in lieu
of the Common Stock (or Other Securities) issuable on such exercise prior to such consummation or such effective date, the stock and other securities and property (including cash) to which such Holder would have been entitled upon such consummation
or in connection with such dissolution, as the case may be, if such Holder had so exercised this Warrant, immediately prior thereto, all subject to further adjustment thereafter as provided in Section 4. 
  
 3.2 Dissolution. In the event of any dissolution of the Company
following the transfer of all or substantially all of its properties or assets, the Company, concurrently with any distributions made to holders of its Common Stock, shall at its expense deliver or cause to be delivered to the Holder the stock and
other securities and property (including cash, where applicable) receivable by the Holder pursuant to Section 3.1, or, if the Holder shall so instruct the Company, to a bank or trust company specified by the Holder and having its principal office in
New York, NY as trustee for the Holder. 
  
 3.3 Continuation of
Terms. Upon any reorganization, consolidation, merger or transfer (and any dissolution following any transfer) referred to in this Section 3, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the
shares of stock and other securities and property receivable on the exercise of this Warrant after the consummation of such reorganization, consolidation or merger or the effective date of dissolution following any such transfer, as the case may be,
and shall be binding upon the issuer of any such stock or other securities, including, in the case of any such transfer, the person acquiring all or substantially all of the properties or assets of the Company, whether or not such person shall have
expressly assumed the terms of this Warrant as provided in Section 4. In the event this Warrant does not continue in full force and effect after the consummation of the transactions described in this Section 3, then the Company’s securities and
property (including cash, where applicable) receivable by the Holder will be delivered to the Holder or the Trustee as contemplated by Section 3.2. 
  
 4. Extraordinary Events Regarding Common Stock. In the event that the Company shall (a) issue additional shares of the Common Stock as a dividend
or other distribution on outstanding Common Stock or any preferred stock issued by the Company, (b) subdivide its outstanding shares of Common Stock, (c) combine its outstanding shares of the Common Stock 
  

 5 

 into a smaller number of shares of the Common Stock, then, in each such event, the Exercise Price shall, simultaneously
with the happening of such event, be adjusted by multiplying the then Exercise Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such event and the denominator of which shall
be the number of shares of Common Stock outstanding immediately after such event, and the product so obtained shall thereafter be the Exercise Price then in effect. The Exercise Price, as so adjusted, shall be readjusted in the same manner upon the
happening of any successive event or events described herein in this Section 4. The number of shares of Common Stock that the holder shall thereafter, on the exercise hereof as provided in Section 1, be entitled to receive shall be adjusted to a
number determined by multiplying the number of shares of Common Stock that would otherwise (but for the provisions of this Section 4) be issuable on such exercise by a fraction of which (a) the numerator is the Exercise Price that would otherwise
(but for the provisions of this Section 4) be in effect, and (b) the denominator is the Exercise Price in effect on the date of such exercise (taking into account the provisions of this Section 4). 
  
 5. Certificate as to Adjustments. In each case of any adjustment or
readjustment in the shares of Common Stock (or Other Securities) issuable on the exercise of this Warrant, the Company at its expense will upon the Holder’s request promptly cause its Chief Financial Officer or other appropriate designee to
compute such adjustment or readjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based,
including a statement of (a) the consideration received or receivable by the Company for any additional shares of Common Stock (or Other Securities) issued or sold or deemed to have been issued or sold, (b) the number of shares of Common Stock (or
Other Securities) outstanding or deemed to be outstanding, and (c) the Exercise Price and the number of shares of Common Stock to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as
adjusted or readjusted as provided in this Warrant. The Company will forthwith mail a copy of each such certificate to the holder and any Warrant agent of the Company (appointed pursuant to Section 11 hereof). 
  
 6. Reservation of Stock, Etc., Issuable on Exercise of Warrant. The
Company will at all times reserve and keep available, solely for issuance and delivery on the exercise of this Warrant, shares of Common Stock (or Other Securities) from time to time issuable on the exercise of this Warrant. 
  
 7. Assignment; Exchange of Warrant. Subject to compliance with
applicable securities laws, this Warrant, and the rights evidenced hereby, may be transferred by any registered holder hereof (a “Transferor”) in whole or in part. On the surrender for exchange of this Warrant, with the Transferor’s
endorsement in the form of Exhibit B attached hereto (the “Transferor Endorsement Form”) and together with evidence reasonably satisfactory to the Company demonstrating compliance with applicable securities laws, which shall include,
without limitation, a legal opinion from the Transferor’s counsel (at the Company’s expense) that such transfer is exempt from the registration requirements of applicable securities laws, the Company at its expense (but with payment by the
Transferor of any applicable transfer taxes) will issue and deliver to or on the order of the Transferor thereof a new Warrant of like tenor, in the name of the Transferor and/or the transferee(s) specified in such Transferor Endorsement 

 

 6 

 Form (each a “Transferee”), calling in the aggregate on the face or faces thereof for the number of shares of
Common Stock called for on the face or faces of the Warrant so surrendered by the Transferor. 
  
 8. Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of
this Warrant, on delivery of an indemnity agreement or security reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation of this Warrant, the Company at its expense will execute
and deliver, in lieu thereof, a new Warrant of like tenor. 
  
 9.
Registration Rights. The Holder has been granted certain registration rights by the Company. These registration rights are set forth in a Registration Rights Agreement entered into by the Company and Holder dated as of the date hereof, as the
same may be amended, modified and/or supplemented from time to time. 
  
 9.1 Maximum Exercise. Notwithstanding anything contained herein to the contrary, the Holder shall not be entitled to exercise this Warrant in connection with that number of shares of Common Stock which would exceed the difference
between (i) 4.99% of the issued and outstanding shares of Common Stock and (ii) the number of shares of Common Stock beneficially owned by the Holder. For purposes of the immediately preceding sentence, beneficial ownership shall be determined in
accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulation 13d-3 thereunder. The limitation described in the first sentence of this Section 10 shall automatically become null and void without any notice to the
Company upon the occurrence and during the continuance of an Event of Default (as defined in the Security Agreement dated as of the date hereof among the Holder, the Company and various subsidiaries of the Company, as amended, modified, restated
and/or supplemented from time to time), or upon 75 days prior notice to the Company. 
  
 10. Warrant Agent. The Company may, by written notice to the each Holder of the Warrant, appoint an agent for the purpose of issuing Common Stock (or Other Securities) on the exercise of this Warrant pursuant
to Section 1, exchanging this Warrant pursuant to Section 7, and replacing this Warrant pursuant to Section 8, or any of the foregoing, and thereafter any such issuance, exchange or replacement, as the case may be, shall be made at such office by
such agent. 
  
 11. Transfer on the Company’s Books.
Until this Warrant is transferred on the books of the Company, the Company may treat the registered holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. 
  
 12. Notices, Etc. All notices and other communications from the
Company to the Holder shall be mailed by first class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company in writing by such Holder or, until any such Holder furnishes to the Company an address,
then to, and at the address of, the last Holder who has so furnished an address to the Company. 
  

 7 

 13. Miscellaneous. This Warrant and any term hereof may be changed, waived, discharged or
terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS WARRANT SHALL BE BROUGHT ONLY IN STATE COURTS OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK;
PROVIDED, HOWEVER, THAT THE HOLDER MAY CHOOSE TO WAIVE THIS PROVISION AND BRING AN ACTION OUTSIDE THE STATE OF NEW YORK. The individuals executing this Warrant on behalf of the Company agree to submit to the jurisdiction of such courts and waive
trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees and costs. In the event that any provision of this Warrant is invalid or unenforceable under any applicable statute or rule of
law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law
shall not affect the validity or enforceability of any other provision of this Warrant. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. The invalidity or
unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision hereof. The Company acknowledges that legal counsel participated in the preparation of this Warrant and, therefore, stipulates that
the rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation of this Warrant to favor any party against the other party. 
  
 14. Call. If the Company shall have registered the shares of the
Common Stock underlying the conversion of the Note (as defined in the Securities Purchase Agreement, the Minimum Borrowing Note (as defined in the Security Agreement) and each Warrant on a registration statement declared effective by the SEC and
remaining effective, then, if the average closing price of the Common Stock as reported by Bloomberg, L.P. on the Principal Market for the preceding twenty consecutive (20) trading days for the Company’s Common Stock is equal to or greater than
140% of the IPO Price, the Company may, in the exercise of its discretion, require the exercise of this Warrant in whole or in part, as set forth herein, by delivering a written Notice to Holder (“Notice of Call”). Any warrants not
exercised by Holder as required by the Notice of Call within twenty calendar days following the Notice of Call shall automatically terminate and no longer be exercisable. 
  
 [BALANCE OF PAGE INTENTIONALLY LEFT BLANK; 
 SIGNATURE PAGE FOLLOWS] 
  

 8 

 IN WITNESS WHEREOF, the Company has executed this Warrant as of the date first written above. 

 

					
	 	 	 ACCENTIA BIOPHARMACEUTICALS, INC.

			
	 WITNESS:
	 	 	 	 
	 	 	 By:
	 	 /s/ Francis E. O’Donnell, Jr., M.D.

	 	 	 Name:
	 	 Francis E. O’Donnell, Jr., M.D.

	 /s/ Alan Pearce

	 	 Title:
	 	 Chairman & CEO

  

 9 

 EXHIBIT A 
  

FORM OF SUBSCRIPTION 
 (To Be Signed
Only On Exercise Of Warrant) 
  

			
	 TO:
	  	 Accentia Biopharmaceuticals, Inc

		
	 	  	 ____________________

		
	 	  	 ____________________

  

	 	Attention:        Chief	Financial Officer 

  
 The undersigned, pursuant to the provisions set forth in the attached Warrant
(No.            ), hereby irrevocably elects to purchase (check applicable box): 
  

			
	 _______
	  	_______shares of the common stock covered by such warrant; or
		
	 _______
	  	the maximum number of shares of common stock covered by such warrant pursuant to the cashless exercise procedure set forth in Section 2.

  
 The undersigned
herewith makes payment of the full Exercise Price for such shares at the price per share provided for in such Warrant, which is $            . Such payment takes the form of (check
applicable box or boxes): 
  

			
	_______	  	$_______ in lawful money of the United States; and/or
		
	_______	  	the cancellation of such portion of the attached Warrant as is exercisable for a total of              shares of Common
Stock (using a Fair Market Value of $             per share for purposes of this calculation); and/or
		
	_______	  	the cancellation of such number of shares of Common Stock as is necessary, in accordance with the formula set forth in Section 2.2, to exercise this Warrant with respect to the maximum number
of shares of Common Stock purchasable pursuant to the cashless exercise procedure set forth in Section 2.

  
 The undersigned
requests that the certificates for such shares be issued in the name of, and delivered to
                                        
                     whose address is
                                        
                                        
                    . 
  
 The undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall
be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the “Securities Act”) or pursuant to an exemption from registration under the Securities Act. 
  

					
	 Dated:
                                    
	 	  

	 	 	(Signature must conform to name of holder as specified on the face of the Warrant)
			
	 	 	 Address:
	 	  

			
	 	 	 	 	  

  

 10 

 EXHIBIT B 
  

FORM OF TRANSFEROR ENDORSEMENT 
 (To
Be Signed Only On Transfer Of Warrant) 
  
 For value received, the
undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees” the right represented by the within Warrant to purchase the percentage and number of shares of Common Stock of Accentia
Biopharmaceuticals, Inc. into which the within Warrant relates specified under the headings “Percentage Transferred” and “Number Transferred,” respectively, opposite the name(s) of such person(s) and appoints each such person
Attorney to transfer its respective right on the books of Accentia Biopharmaceuticals, Inc. with full power of substitution in the premises. 
  

							
	 Transferees

	 	 Address

	 	 Percentage
 Transferred

	  	Number Transferred

  
  
  
  
  
  

					
	 Dated:
                            
	 	  

	 	 	(Signature must conform to name of holder as specified on the face of the Warrant)
			
	 	 	 Address:
	 	  

			
	 	 	 	 	  

		
	 	 	 SIGNED IN THE PRESENCE OF:

		
	 	 	  

	 	 	(Name)

  

	
	 ACCEPTED AND AGREED:
 [TRANSFEREE]

	
	  

	(Name)

  

 11Omnibus Amendment and Consent, dated 8/16/05

 Exhibit 10.80 
  
 OMNIBUS AMENDMENT AND CONSENT 
  

This Omnibus Amendment and Consent (this “Amendment”), dated as of August 16, 2005, by and between Accentia Biopharmaceuticals, Inc., a
Florida corporation (the “Company”), and Laurus Master Fund, Ltd., a Cayman Islands company (the “Purchaser”), amends that certain Securities Purchase Agreement, dated as of April 29, 2005 (the “Initial
Closing Date”), by and between the Company and the Purchaser (the “Securities Purchase Agreement”); that certain Registration Rights Agreement, dated as of April 29, 2005, by and between the Company and the Purchaser (the
“Registration Rights Agreement”); and that certain Secured Convertible Term Note, dated as of April 29, 2005, by the Company in favor of Purchaser for the total principal amount of $5,000,000 (the “Term Note”,
collectively, with the Securities Purchase Agreement, and the Registration Rights Agreement, the “Funding Documents”). Capitalized terms used but not defined herein shall have the meanings given them in the Securities Purchase
Agreement. 
  
 PREAMBLE 
  
 WHEREAS, pursuant to the Funding Documents, the Purchaser agreed to
loan to the Company as of the Initial Closing Date and pursuant to the Term Note, a total principal amount of $5,000,000 (the “Initial Term Loan Amount”); the Term Note is convertible into shares of the Company’s common stock
(the “Note Shares”) at an initial fixed conversion price of $3.30; 
  
 WHEREAS, the Company has requested that the Purchaser loan to the Company an additional $5,000,000 so as to increase the Initial Term Loan Amount and pursuant to the terms and conditions set forth herein, the
Purchaser is willing to increase the Initial Term Loan Amount to $10,000,000 and, in consideration therefor and in consideration of the other agreements set forth herein, the receipt and sufficiency of which is hereby acknowledged, the Company has
agreed to issue the Additional Penny Warrant (as defined below) and amend and restate the original Warrant issued to the Purchaser on April 29, 2005; 
  
 NOW, THEREFORE, in consideration of the covenants, agreements and conditions hereinafter set forth, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  
 1. Amendments and Agreement. 
  

	 	(i)	Effective as of the Amendment Effective Date (as defined below), the Term Note is hereby amended and restated in the form attached hereto as Exhibit A (the “Amended
and Restated Term Note”). For the avoidance of doubt, the amendment and restatement of the Term Note as set forth in this Section 1(i) shall be in substitution for and not in satisfaction of the Term Note; 

	 	(ii)	Pursuant to the escrow agreement in the form attached hereto as Exhibit B (the “Follow On Escrow Agreement”), on the Amendment Effective Date, the Company
will deliver to the Purchaser, among other things, the Amended and Restated Term Note, the Additional Penny Warrant and the Amended and Restated Warrant, and the Purchaser will deliver to the Company (or to such other recipients as may be directed
by the Company), among other things, the amounts set forth in the Disbursement Letter (attached hereto as Exhibit C) by certified funds or wire transfer. 

  

	 	(iii)	On the Amendment Effective Date, in further consideration of the amendments in this Section 1 and the additional extension of credit to be made by the Purchaser to the Company as
contemplated herein, the Company shall issue a ten year warrant (the “Additional Penny Warrant”) to the Purchaser to purchase up to 277,778 shares of the common stock of the Company with an exercise price of $0.001, such Additional
Penny Warrant to be in the form attached hereto as Exhibit D; 

  

	 	(iv)	On the Amendment Effective Date, in further consideration of the amendments in this Section 1 and the additional extension of credit to be made by the Purchaser to the Company as
contemplated herein, the Company shall amend and restate the Warrant in the form attached hereto as Exhibit E (as amended and restated, the “Amended and Restated Warrant”); 

  

	 	(v)	Promptly after occurrence of the Amendment Effective Date, the original Term Note and original Warrant which are replaced with the Amended and Restated Term Note and Amended and
Restated Warrant shall be returned to the Company. 

  
 2. Acknowledgments and Agreements with respect to various Related Agreements. 
  

	 	(i)	For the avoidance of doubt, each of the Company, The Analytica Group, Inc. (“Analytica”) and TEAMM Pharmaceuticals, Inc. (“TEAMM” and, together
with the Company and Analytica, the “Credit Parties” and, each a “Credit Party”) hereby acknowledges and confirms its due authorization, execution and delivery of the Securities Purchase Agreement and all Related
Agreements referred to therein (each as amended, restated, modified and/or supplemented through and including the date hereof) to which it is a party, including all instruments, financing statements, agreements, certificates and documents executed
and delivered in connection therewith, and hereby ratifies all actions heretofore taken in connection therewith, including, without limitation, the acknowledgement, ratification and confirmation of the grant by each such Credit Party to the
Purchaser of a security interest and charge, to the extent applicable, in the assets of such Credit Party as more specifically set forth in the Securities Purchase Agreement and the Related Agreements referred to therein; 

 

 2 

	 	(ii)	Each Credit Party, by its execution (or acknowledgment, as the case may be) and delivery of this Amendment, hereby consents to the extensions of credit pursuant to the Securities
Purchase Agreement and the Related Agreements (including, without limitation, as amended by this Amendment). Each Credit Party further acknowledges and agrees to the provisions of this Amendment and hereby agrees for the benefit of the Purchaser
that all extensions of credit (including as contemplated by this Amendment) pursuant to the Securities Purchase Agreement and the Related Agreements (including, without limitation, as amended by this Amendment, and as same may be further amended,
restated, modified and/or supplemented from time to time) shall be fully entitled to all benefits of, and shall be fully guaranteed and secured pursuant to and in accordance with the terms of, each of the Securities Purchaser Agreement and the
Related Agreements, as applicable. Each Credit Party further acknowledges, ratifies and confirms that the obligations and liabilities under the Amended and Restated Term Note constitute “Obligations” under the Stock Pledge Agreement, the
Subsidiary Guaranty, the Master Security Agreement and the Note Pledge Agreement and the term “Obligations” under the Stock Pledge Agreement, the Subsidiary Guaranty, the Master Security Agreement and the Note Pledge Agreement include,
without limitation, all obligations and liabilities of the Credit Parties to the Purchaser under the Securities Purchase Agreement and the Related Agreements (as defined therein) and all other obligations and liabilities of the undersigned to the
Purchaser (including interest accruing after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, whether or not a claim for post-filing or post-petition interest is allowed or allowable
in such proceeding), whether now existing or hereafter arising, direct or indirect, liquidated or unliquidated, absolute or contingent. 

  

	 	(iii)	Laurus hereby acknowledges and agrees that, (I) notwithstanding anything to the contrary set forth in the Securities Purchase Agreement or the Related Agreements referred to
therein, the Company shall be permitted to incur up an aggregate amount at any time outstanding of no more than $7,5,000,000 of unsecured, convertible indebtedness (“Qualified Unsecured Borrowings”) from Hopkins Capital Group II, LLC
(collectively, the “Affiliate Lenders”) prior to the completion of an underwritten initial public offering of the Company’s Common Stock, par value $.001 per share, pursuant to a Registration Statement on Form S-1 originally filed on
February 11, 2005, as amended (Registration No. 33-122769) (the “Offering”); and (II) the Company shall be permitted to repay to the Affiliate Lenders the outstanding Qualified Unsecured Borrowings to the extent outstanding; provided that
(i) no Event of Default has occurred and is continuing at such time of payment, both before and after giving effect to such payment, and (ii) at such time of proposed repayment, the total principal amount of indebtedness owed by the Company to
Purchaser does not exceed $2,500,000.. 

  

 3 

	 	(iv)	The parties hereto each acknowledge that subsequent to the Initial Closing Date, on May 16, 2005, the Company affected a 1 for 2.1052 reverse stock split (the “Reverse
Split”) of its Common Stock. Except in respect of the Amended and Restated Term Note and the Amended and Restated Warrant entered into as part of this Amendment, the Securities Purchase Agreement and the other Related Agreements, references
related to the Common Stock of the Company are determined prior to effectiveness of the Reverse Split and are subject to adjustment pursuant to the applicable terms therein (if any) addressing adjustment as a result of a reverse stock split.

  
 3. Effectiveness. This Amendment shall be
effective as of the date (the “Amendment Effective Date”) when: 
  

	 	(i)	Each Credit Party and Laurus shall have executed and each Credit Party shall have delivered to the Purchaser its respective counterpart to this Amendment and the Escrow Agreement;

  

	 	(ii)	the Purchaser shall have received from each Credit Party, true and correct certified copies of resolutions of the Board of Directors (or equivalent) of such Person with respect to
the matters set forth in this Amendment, and such resolutions shall be in form and substance satisfactory to the Purchaser; 

  

	 	(iii)	the Company shall have delivered to the Purchaser evidence in form and substance satisfactory to the Purchaser that (I) the maximum aggregate principal amount permitted to be drawn
under its existing line of credit with the Affiliate Lenders (the “Hopkins Line”) shall have been increased to no less than $7,5,000,000 (it being understood that as of the date hereof, no more than $5,000,000 shall be outstanding
thereunder) and (II) the Hopkins Line shall remain irrevocable, and the maximum amount permitted to be drawn thereunder shall not be reduced, by any Affiliate Lender until such time as the total principal amount of indebtedness owed by the Company
to Purchaser is less than or equal to $2,500,000 or the Company has completed an public offering; 

  

	 	(iv)	the Company shall have delivered to the Purchaser evidence in form and substance satisfactory to the Purchaser that Pharmaceutical Product Development, Inc. (“PPDI”) shall
have unconditionally exercised its rights under certain common stock purchase warrants of the Company (the “PPDI Warrants”) it holds and that the Company shall have received from PPDI cash proceeds equal to no less than $5,000,000, on an
unconditional basis, in satisfaction of the exercise price of such PPDI Warrants; 

  

	 	(v)	the Company shall have delivered to the Purchaser evidence in form and substance satisfactory to the Purchaser that McKesson Corporation shall 

  

 4 

 have consented in writing to the additional extension of credit by the Purchaser to the Company as
described in the recitals hereto and shall have agreed to increase the permitted maximum principal amount of the “Senior Liabilities” referred to in the Subordination Agreement, dated as of April 29, 2005 between McKesson Corporation from
$10,000,000 to no less than $15,000,000; 
  

	 	(vi)	the Company shall have delivered to the Purchaser evidence in form and substance satisfactory to the Purchaser of (I) the pledge to the purchaser by The Francis E. O’Donnell,
Jr. Irrevocable Trust No. 1 (the “O’Donnell Trust”) of no less than 1,000,000 additional shares of common stock of Star Scientific, Inc. (the “Additional Pledged Shares”), (II) the due execution and delivery of an amendment
to the O’Donnell Stock Pledge Agreement, dated as of April 29, 2005 between the O’Donnell Trust and the Purchaser evidencing the additional pledge of the Additional Pledged Shares (III) delivery to Purchaser of the original share
certificates evidencing the Additional Pledged Shares together with undated stock powers executed in blank; 

  

	 	(vii)	the Company shall have provided the Purchaser with evidence reasonably satisfactory to the Purchaser that the requisite consent of the holder’s of the Company’s Series E
preferred stock has been obtained in respect of the consummation of the transactions described herein, including, without limitation, the granting to the Purchaser of registration rights pursuant to the terms of the Registration Rights Agreement;

  

	 	(viii)	the Company shall have executed and delivered to the Purchaser each of the Amended and Restated Term Note, the Escrow Agreement, the Additional Penny Warrant and the Additional
Warrant; and 

  

	 	(ix)	the Company shall have provided the Purchaser with an opinion of counsel in form and substance satisfactory to the Purchaser addressing such matters as shall arise in connection
with this Amendment and the transactions described herein. 

  
 4. Miscellaneous. 
  

	 	(i)	Except as specifically set forth in this Amendment, there are no other amendments to the Term Note, and all of the other forms, terms and provisions of the Term Note remain in full
force and effect. 

  

	 	(ii)	The Company hereby represents and warrants to the Purchaser that (i) no Event of Default exists on the date hereof, after giving effect to this Amendment, (ii) on the date hereof,
after giving effect to this Amendment, all representations, warranties and covenants made by the Company in connection with the Loan Documents are 

  

 5 

 true, correct and complete, (iii) on the date hereof, after giving effect to this Amendment, all of the
Company’s and its Subsidiaries’ covenant requirements have been met and (iv) neither the Company, nor any of its Subsidiaries or affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales
of any security or solicited any offers to buy any security (other than an offering the Purchaser under a Security Agreement between the Parent and Laurus the Purchaser dated as of April 29, 2005 (as amended, modified and/or supplemented from time
to time, the “Security Agreement”)) under circumstances that would cause the offering of the Securities pursuant to this Securities Purchase Agreement, any of the Related Agreements or the initial public offering of the Parent’s
Common Stock to be determined to be integrated with prior offerings by the Parent for purposes of the Securities Act which would (x) prevent the Parent from selling the Securities pursuant to Rule 506 under the Securities Act, or any applicable
exchange-related stockholder approval provisions or (y) give rise to, for the benefit of the holders of any security of the Parent received through any such offering or sale, the right of rescission of such offering or sale, nor will the Parent or
any of its affiliates or Subsidiaries take any action or steps that would cause the offering of the Securities or the securities to be issued in connection with the initial public offering of the Parent’s Common Stock to be integrated with
other offerings. 
  

	 	(iii)	From and after the Amendment Effective Date, all references in the Funding Documents and in the other Related Agreements referred to in the Securities Purchase Agreement, shall be
deemed to be references to such documents as modified and to the extent modified hereby. 

  

	 	(iv)	This Amendment shall be binding upon the parties hereto and their respective successors and permitted assigns and shall inure to the benefit of and be enforceable by each of the
parties hereto and its successors and permitted assigns. THIS AMENDMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK. This Amendment may be executed in any number of counterparts, each of which
shall be an original, but all of which shall constitute one instrument. 

  
 [signature page follows] 
  

 6 

 IN WITNESS WHEREOF, each of the parties hereto has executed this Amendment or has caused this
Amendment to be executed on its behalf by a representative duly authorized, all as of the date first above set forth. 
  

							
	COMPANY:	 	PURCHASER:
		
	ACCENTIA BIOPHARMACEUTICALS, INC.	 	LAURUS MASTER FUND, LTD.
				
	By:	 	 /s/ Francis E. O’Donnell

	 	By:	 	 /s/ Eugene Grin

	Name:	 	Francis E. O’Donnell	 	Name:	 	Eugene Grin
	Title:	 	Chief Executive Officer	 	Title:	 	Director

  
  
 AGREED AND ACKNOWLEDGED: 
  
 THE ANALYTICA GROUP, INC. 
  

			
	By:	 	 /s/ Steve Arikian

	Name:	 	Steve Arikian
	Title:	 	Chairman and CEO

  
 TEAMM PHARMACEUTICALS, INC.

  

			
	By:	 	 /s/ Martin Baum

	Name:	 	Martin Baum
	Title:	 	President

  

 7 

 ANNEX A 
  
 AMENDED AND RESTATED TERM NOTE 

 ANNEX B 
  
 ESCROW AGREEMENT 

 EXHIBIT C 
  
 DISBURSEMENT LETTER 

 ANNEX D 
  
 ADDITIONAL PENNY WARRANT 

 ANNEX E 
  
 AMENDED AND RESTATED WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]